Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Nature Medicine|June 2, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trialJavier Cortés, Sara A Hurvitz, Seock-Ah Im, et al.
JCO Oncology Practice|November 8, 2021
Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement EffortSarah F D'Ambruoso, John A Glaspy, Sara A Hurvitz, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket TrialKomal Jhaveri, Lisa D Eli, Sara A Hurvitz, et al.
NPJ Breast Cancer|October 6, 2023
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO studyNicholas C Turner, A Douglas Laird, Melinda L Telli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast CancerCristina Saura, Judit Matito, Mafalda Oliveira, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2022
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancerSibylle Loibl, Delphine Loirat, Sara M Tolaney, et al.
The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
Pageof 14